Patents by Inventor Motokazu Tsujikawa

Motokazu Tsujikawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Corneal endothelial cell marker and use thereof
    Patent number: 11839697
    Abstract: Provided is a means for identifying cells suitable for transplantation into a cornea, or a means for producing a cell population suitable for transplantation into a cornea using the same. A method for producing a cell population suitable for transplantation into a cornea, the method comprising the steps of (1) preparing a cell population cultured under conditions suitable for inducing differentiation into corneal endothelial cells, and (2) measuring the expression of at least one gene selected from the group consisting of POU6F2, LMX1B, and TFAP2B in the cell population.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: December 12, 2023
    Assignee: OSAKA UNIVERSITY
    Inventors: Kohji Nishida, Motokazu Tsujikawa, Susumu Hara, Satoshi Kawasaki, Masahito Yoshihara, Masayoshi Itoh, Hideya Kawaji
  • Corneal endothelial cell marker
    Patent number: 10968428
    Abstract: A molecular marker expressed specifically in corneal endothelial cells, and a method for producing one or more corneal endothelial cells using the marker and a method for evaluating one or more corneal endothelial cells using the marker are provided. At least one molecule selected from the group consisting of ZP4, MRGPRX3, GRIP1, GLP1R, HTR1D, and CLRN1 is used as a marker specific to corneal endothelial cells.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: April 6, 2021
    Assignee: OSAKA UNIVERSITY
    Inventors: Kohji Nishida, Motokazu Tsujikawa, Susumu Hara, Satoshi Kawasaki, Masahito Yoshihara, Masayoshi Itoh, Hideya Kawaji, Hiroko Ohmiya
  • CORNEAL ENDOTHELIAL CELL MARKER AND USE THEREOF
    Publication number: 20200101200
    Abstract: Provided is a means for identifying cells suitable for transplantation into a cornea, or a means for producing a cell population suitable for transplantation into a cornea using the same. A method for producing a cell population suitable for transplantation into a cornea, the method comprising the steps of (1) preparing a cell population cultured under conditions suitable for inducing differentiation into corneal endothelial cells, and (2) measuring the expression of at least one gene selected from the group consisting of POU6F2, LMX1B, and TFAP2B in the cell population.
    Type: Application
    Filed: June 19, 2018
    Publication date: April 2, 2020
    Inventors: Kohji Nishida, Motokazu Tsujikawa, Susumu Hara, Satoshi Kawasaki, Masahito Yoshihara, Masayoshi Itoh, Hideya Kawaji
  • CORNEAL ENDOTHELIAL CELL MARKER
    Publication number: 20170253855
    Abstract: A molecular marker expressed specifically in corneal endothelial cells, and a method for producing one or more corneal endothelial cells using the marker and a method for evaluating one or more corneal endothelial cells using the marker are provided. At least one molecule selected from the group consisting of ZP4, MRGPRX3, GRIP1, GLP1R, HTR1D, and CLRN1 is used as a marker specific to corneal endothelial cells.
    Type: Application
    Filed: September 4, 2015
    Publication date: September 7, 2017
    Applicant: OSAKA UNIVERSITY
    Inventors: Kohji NISHIDA, Motokazu TSUJIKAWA, Susumu HARA, Satoshi KAWASAKI, Masahito YOSHIHARA, Masayoshi ITOH, Hideya KAWAJI, Hiroko OHMIYA
  • Methods for treating a disease caused by choroidal neovascularization
    Patent number: 8975229
    Abstract: The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and/or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: March 10, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Motokazu Tsujikawa, Yusuke Nakamura, Takuya Tsunoda
  • VACCINE THERAPY FOR CHOROIDAL NEOVASCULARIZATION
    Publication number: 20120156233
    Abstract: The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and/or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.
    Type: Application
    Filed: June 10, 2010
    Publication date: June 21, 2012
    Applicant: OncoTherapy Science, Inc.
    Inventors: Motokazu Tsujikawa, Yusuke Nakamura, Takuya Tsunoda